UNC0321

UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 63 pM and with assay-dependent IC50 values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC50 values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications[1][3].

Product Specifications

CAS Number

[1238673-32-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; GCGR; Histone Methyltransferase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/UNC0321.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN1CCC(NC2=C3C=C(OC)C(OCCOCCN(C)C)=CC3=NC(N4CCN(C)CCC4)=N2)CC1

Molecular Formula

C27H45N7O3

Molecular Weight

515.69

Precautions

H302, H315, H319, H335

References & Citations

[1]Liu F, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53 (15) :5844-57.|[2]Liu F, et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J Med Chem. 2011 Sep 8;54 (17) :6139-50.|[3]Nie J. UNC0321 inhibits high glucose induced apoptosis in HUVEC by targeting Rab4. Biomed Pharmacother. 2020 Nov;131:110662.